Short Interest in Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Declines By 55.9%

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) saw a significant decrease in short interest in the month of October. As of October 15th, there was short interest totalling 21,300 shares, a decrease of 55.9% from the September 30th total of 48,300 shares. Currently, 2.6% of the company’s stock are sold short. Based on an average daily trading volume, of 66,400 shares, the short-interest ratio is presently 0.3 days.

Phio Pharmaceuticals Trading Down 1.7 %

Shares of PHIO stock traded down $0.05 on Friday, hitting $2.91. 25,775 shares of the stock were exchanged, compared to its average volume of 43,726. The firm has a market capitalization of $1.48 million, a P/E ratio of -0.10 and a beta of 1.45. The business has a 50-day moving average of $3.05 and a 200 day moving average of $4.72. Phio Pharmaceuticals has a fifty-two week low of $2.40 and a fifty-two week high of $18.81.

Phio Pharmaceuticals (NASDAQ:PHIO) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($3.62) earnings per share for the quarter, topping the consensus estimate of ($4.59) by $0.97.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.